MedTrace Logo

Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth

NCT01748929 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1010

Last updated 2017-08-29

No results posted yet for this study

Summary

Women of reproductive age are considered a high-risk group for worm infections by the World Health Organization. Maternal infection and anemia contribute to infant malnutrition by affecting milk quality and quantity, and duration of exclusive breastfeeding. To date, no study has investigated the health benefits of postpartum deworming to infants or mothers. A randomized controlled trial will be conducted in Peru to investigate the effectiveness of integrating deworming into routine postpartum care. The primary measure of effect will be infant weight gain between birth and six months of age. Other infant and maternal health indicators will also be ascertained.

Conditions

  • Intestinal Diseases, Parasitic

Interventions

DRUG

Albendazole

DRUG

Placebo

Sponsors & Collaborators

  • McGill University Health Centre/Research Institute of the McGill University Health Centre

    lead OTHER

Principal Investigators

  • Theresa W Gyorkos, PhD · McGill University Health Centre/Research Institute of the McGill University Health Centre

  • Martin Casapia, MD, MPH · Asociación Civil Selva Amazónica

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-02-24
Primary Completion
2015-02-13
Completion
2016-09-16

Countries

  • Peru

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01748929 on ClinicalTrials.gov